TAS-102
- Generic Name
- TAS-102
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 733030-01-8
- Unique Ingredient Identifier
- -
- Background
TAS-102 (Taiho Pharma USA, Inc.) is an anti-cancer drug under development and in stage 3 clinical trials for the treatment of colorectal cancer. It is composed of the thymidine phosphorylase inhibitor (TPI) tipiracil and the cytotoxin trifluridine. Trifluridine inhibits tumor growth by being incorporated into DNA during DNA synthesis. Tipiracil prevents trif...
- Indication
用于治疗曾经接受氟嘧啶，奥沙利铂和伊立替康为基础的化疗，抗VEGF生物治疗和抗EGFR治疗（如果是RAS野生型）无效的转移性结直肠癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 589
- Registration Number
- NCT06346392
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Holy Stone Healthcare Co., Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06039202
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
- Conditions
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05600309
- Locations
- 🇨🇳
Hainan General Hospital ( Site 1177), Haikou, Hainan, China
🇨🇳Fujian Province Cancer Hospital ( Site 1178), Fuzhou, Fujian, China
🇨🇳The Sixth Affiliated Hospital of Sun Yat-sen University ( Site 1159), Guangzhou, Guangdong, China
Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 20
- Registration Number
- NCT05481463
- Locations
- 🇨🇳
Cancer center of SunYat-sen University, Guangzhou, Guangdong, China
Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
- Conditions
- Interventions
- First Posted Date
- 2022-05-02
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Academic and Community Cancer Research United
- Registration Number
- NCT05356897
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, San Diego, California, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
TAS-102 in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05343013
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 700
- Registration Number
- NCT05328908
- Locations
- 🇧🇪
Local Institution - 0120, Leuven, Belgium
🇨🇭Local Institution - 0057, Aarau, AG, Switzerland
🇧🇪Local Institution - 0070, Edegem, Belgium
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-06
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT05314101
- Locations
- 🇨🇳
FujianCH, Fuzhou, Fujian, China
Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05266820
- Locations
- 🇨🇳
First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Fuzhou First Hospital affiliated to Fujian Medical University, Fuzhou, China
🇨🇳The Third People's Hospital affiliated to Fujian University of Chinese Medicine, Fuzhou, China
A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer
- Conditions
- Metastatic Microsatellite Stable Colorectal CarcinomaMicrosatellite Stable Rectal CarcinomaStage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Metastatic Colon AdenocarcinomaMetastatic Colorectal CarcinomaMetastatic Microsatellite Stable Colon CarcinomaMetastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 15
- Registration Number
- NCT05130060
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.